Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 30, 1998

View Archived Issues

Somatogen: Q2 1998 highlights and clinical trial update

Phase III results reported for Prosorba

Prokinetic motilin agonists in development at Ohmeda

Novel class of muscarinic receptor agonists described by Pfizer

Lilly patents new voltage-sensitive calcium channel antagonists for CNS disorders

Diosmetin derivatives for vascular disorders prepared at ADIR

Novel chemokine identified and characterized at Millennium

Vitamin D analogues disclosed by Roche for hyperproliferative disorders

New antifungals reported by J&J subsidiary

Phase II results reported for memantine in neuropathic pain

Roche patents vitamin D analogues for osteoporosis

Oxytocin antagonist licensed by Tokyo Tanabe enters clinic

Tanabe's Tanatril receives E.U. approval

Schering-Plough to copromote Novo Nordisk's Prandin

Antiemetic to be copromoted in Japan by Novartis and Kyowa Hakko

Phase I/II trial results reported for Neovastat in lung cancer

Complete efficacy reported for Viratrol in recurrent herpes labialis

Another SMART antibody advances to clinical testing

Aquila receives milestone payment from SKB under Stimulon agreement

Proleukin cleared for marketing in U.S. for melanoma indication

Suramin submitted for FDA approval for cancer indication

Caspase inhibitor reduces ischemia/reperfusion injury, attenuates apoptosis in vivo

Roche acquisition of Corange on track

Pharmacia & Upjohn licenses rights to Spanish antimigraine drug

European approval recommended for Optison

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...